To hear about similar clinical trials, please enter your email below
Trial Title:
A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis
NCT ID:
NCT06007300
Condition:
the Dynamic Evolution of Endometrial Carcinogenesis
Multiomics Analysis
Conditions: Official terms:
Carcinogenesis
Conditions: Keywords:
Dynamic Evolution
Genomics
Transcriptome
Proteomics
Metabolomics
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
The goal of this observational study is to draw the characteristic maps of imaging omics,
genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the
dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium,
100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial
cancer; and then to explore the underlying molecular mechanism, and establish the
database system for the dynamic evolution of endometrial carcinogenesis.
Criteria for eligibility:
Study pop:
Patients with normal endometrium (requiring diagnostic or therapeutic hysteroscopy or
hysterectomy for other reasons), patients with precancerous lesions of endometrium, and
patients with endometrial cancer who underwent surgery in the gynecology and obstetrics
department of Renji Hospital affiliated to Shanghai Jiaotong University School of
Medicine, whose illness was diagnosed as normal endometrium, atypical hyperplasia
endometrium, or endometrial cancer by pathology.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or
endometrial cancer;
- Obtain pathological results after undergoing hysteroscopic surgery or hysterectomy;
- The patient voluntarily participated in this research project with good compliance
and was able to complete the enrollment according to the experimental requirements;
- Sign the informed consent form and consent to the collection and use of their data,
and consent to genomics, transcriptome and other tests.
Exclusion Criteria:
- Patients with malignant tumors in other parts of the body;
- Suffering from uncontrollable neurological diseases, psychiatric diseases, or
psychiatric disorders;
- Poor compliance and inability to cooperate and describe treatment responders.
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
August 2023
Completion date:
June 2026
Lead sponsor:
Agency:
RenJi Hospital
Agency class:
Other
Source:
RenJi Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06007300
